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ORIGINAL INVESTIGATION
The renal tubular damage marker 
urinary N-acetyl-β-d-glucosaminidase may be 
more closely associated with early detection 
of atherosclerosis than the glomerular damage 
marker albuminuria in patients with type 2 
diabetes
So Ra Kim1,2, Yong‑ho Lee1,2, Sang‑Guk Lee3, Eun Seok Kang1,2, Bong‑Soo Cha1,2 and Byung‑Wan Lee1,2*
Abstract 
Background: To determine the association between urinary N‑acetyl‑β‑d‑glucosaminidase (NAG), a marker of renal 
tubulopathy, and carotid intima‑media thickness (IMT) and plaques in patients with type 2 diabetes mellitus (T2D) 
and to compare the predictive value of NAG versus albuminuria, a marker of renal glomerulopathy.
Methods: A total of 343 participants were enrolled in this retrospective cross‑sectional study. We recruited partici‑
pants with T2D who were tested for blood glucose parameters, urinary NAG, and urinary albumin‑to‑creatinine ratio 
(ACR) and had been checked for carotid ultrasonography.
Results: We classified participants into a below‑median urinary NAG group (Group I; n = 172) or an above‑median 
group (Group II; n = 171). Mean, maximum, and mean of maximum carotid IMT and the proportion of patients with 
carotid plaques were significantly higher in Group II compared with Group I. In multiple linear regression analyses, 
high urinary NAG (Group II) was significantly associated with carotid IMT, independently of urinary ACR and other 
confounding factors. In terms of carotid plaques, both urinary NAG and ACR were significantly higher in participants 
with carotid plaques than in those without carotid plaques. After adjustment for confounding factors, both urinary 
NAG and ACR were significantly associated with the presence of carotid plaques.
Conclusions: Elevated urinary NAG, a marker of renal tubular damage, was related to increased carotid IMT and the 
presence of carotid plaques in patients with T2D. Urinary NAG may be a more sensitive biomarker than urinary albu‑
min for early detection of atherosclerosis.
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Background
Cardiovascular disease (CVD) is a major cause of mor-
bidity and mortality in patients with type 2 diabetes 
mellitus (T2D), who have a twofold to fourfold increase in 
CVD incidence compared with patients without diabetes 
[1]. Therefore, the development of methods to estimate 
the risk of CVD in diabetic patients with more accuracy 
is highly desirable and will aid in preventing CVD events. 
Several surrogate measures for CVD that estimate sub-
clinical atherosclerosis have been developed. Acceptable 
surrogates include pulse wave velocity (PWV), which is 
the gold standard for determining arterial stiffness and 
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plays an important role in the occurrence of atheroscle-
rosis [2, 3], carotid artery intima-media thickness (IMT) 
and the presence of carotid plaques, which, despite dif-
ferent pathogenic characteristics, correlate with coronary 
artery disease and stroke [4], and albuminuria, which is 
highly predictive not only of the development of diabetic 
kidney disease (DKD) but also of subsequent CVD and 
death [5]. Furthermore, several previous studies report 
positive independent associations between albuminuria 
and indices of macrovascular complications such as PWV 
and coronary artery calcification in patients with T2D or 
essential hypertension [6–8]. However, the relationship 
between IMT and albuminuria is still controversial [2, 
9]. This controversy might be explained by differences in 
characteristics of study populations such as age, duration 
of diabetes, and ethnic diversity as well as the use of dif-
ferent methods to measure carotid atherosclerotic lesions 
[10].
Recently, several renal tubular damage markers have 
gained considerable attention because of their clinical rel-
evance as sensitive and specific biomarkers for predicting 
the development and progression of early-stage DKD [11, 
12]. The urinary enzyme N-acetyl-β-d-glucosaminidase 
(NAG) exists in the lysosomes of proximal tubule epi-
thelial cells. Increased NAG excretion in urine is caused 
exclusively by proximal tubular cell injury. Furthermore, 
increases in urinary NAG already occur in normal to 
mildly increased albuminuric patients with T2D [11]. 
There is accumulating evidence that urinary NAG is 
correlated or associated not only with nephropathy but 
also with vascular complications of T2D, including retin-
opathy [13], neuropathy [14], and macrovascular disease 
[15]. However, little research has focused on the relation-
ship between urinary NAG excretion and carotid IMT or 
plaques in patients with T2D.
The aim of this study was to investigate the association 
between urinary NAG and carotid IMT and plaques in 
patients with T2D. By comparing the predictive value of 
NAG with that of albuminuria, we also aimed to deter-
mine whether urinary NAG, a marker for renal tubulopa-
thy, is a better predictor of carotid atherosclerosis than 
albuminuria, a marker for renal glomerulopathy.
Methods
Study participants
Using a retrospective cross-sectional design, we recruited 
participants with T2D who attended the Severance Hos-
pital Diabetes Center between March 2015 and March 
2016, had been simultaneously monitored for blood 
glucose parameters, urinary NAG, and albumin-to-cre-
atinine ratio (ACR), and had undergone carotid ultra-
sonography within 1 month before or after the laboratory 
measurements. T2D was defined on the basis of (1) the 
participant’s use of insulin or oral hypoglycemic agents or 
(2) HbA1C ≥ 6.5% (47.5 mmol/mol). We used the follow-
ing inclusion criteria: (1) patients who had regular meas-
urements of blood parameters including HbA1C and (2) 
patients with stable HbA1C indicated by changes of no 
more than 0.5% during the preceding 6 months. Partici-
pants who met the following criteria were excluded: (1) 
<20 years of age; (2) type 1 diabetes; (3) taking a sodium-
glucose co-transporter 2 inhibitor; (4) pregnant women; 
(5) severe liver disease; (6) active cancer; (7) active infec-
tious disease including urinary tract infection; (8) non-
diabetic kidney disease; (9) connective tissue disease; 
(10) valvular heart disease or arrhythmia; (11) anemia 
(hemoglobin < 12 g/dL); or (12) hyper- or hypothyroid-
ism. Age, sex, weight, height, waist circumference, smok-
ing habits, blood pressure, duration of diabetes, and 
current medications were recorded. Body mass index 
(BMI) was calculated as weight divided by height squared 
(kg/m2). Hypertension was defined as a systolic blood 
pressure ≥140 mmHg and/or a diastolic blood pressure 
≥90 mmHg or currently using antihypertensive medica-
tions. Coronary artery disease was defined as a positive 
history of myocardial infarction or proven single- or 
multi-vessel coronary artery disease with or without 
symptoms of angina pectoris. History of coronary artery 
disease or ischemic stroke had to be documented by 
hospital records. The Institutional Review Board at Sev-
erance Hospital approved this study protocol (4-2016-
0480). Written informed consent for this study was not 
required by the Institutional Review Board because the 
database was only accessed for analysis purposes and 
personal information was not used.
Measurements of blood gluco‑metabolic parameters
Following an overnight fast, blood tests for glucose (des-
ignated as basal glucose), HbA1C, glycated albumin (GA), 
lipid profiles, white blood cell count, uric acid, and creati-
nine were performed. For measurements of postprandial 
glucose (designated as stimulated glucose), participants 
were administered a mixed-meal test, with blood sam-
ples collected 90  min after ingestion of two cans (total 
400 mL, 400 kcal, 18 g fat, 44 g carbohydrate, and 20 g 
protein) of a standardized mixed-meal (Mediwell Dia-
betic MealTM, Meail Dairies Co., Yeongdong-gun, 
Chungbuk, Korea), or glucose was measured in blood 
collected 2 h after a normal meal. HbA1c was measured 
by immunoassay using an Integra 800 CTS (Roche, Her-
cules, CA, USA). Serum GA levels were determined by an 
enzymatic method (LUCICA GA-L, Asahi Kasei Pharma 
Co., Tokyo, Japan) using a Hitachi 7600 auto-analyzer 
(Hitachi Ltd., Tokyo, Japan). Serum glucose and creati-
nine were also measured using the Hitachi 7600 ana-
lyzer (Hitachi Ltd.). For serum creatinine, a compensated 
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kinetic Jaffe method (Clinimate CRE, Sekisui Medical 
Co., Ltd., Japan) was used, in which the creatinine con-
centration was standardized to isotope dilution-mass 
spectrometry. The estimated glomerular filtration rate 
(eGFR) was derived from the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI).
Measurements of urinary glomerular and tubular damage 
markers
Urinary NAG, albumin, and creatinine levels were meas-
ured in a fasting morning spot urine sample that was 
obtained from each participant. Urinary NAG and albu-
min levels were expressed as urinary NAG-to-creatinine 
ratio and ACR to minimize the influence of variations 
in kidney function. The urine NAG level was measured 
by a colorimetric method using a reagent from Nit-
tobo Medial Co., Ltd. (Tokyo, Japan) and a JCA-BM 
6010/c automated chemistry analyzer (JEOL Ltd., Tokyo, 
Japan). In this assay, the substrate 6-methyl-2-pyridyl-
N-acetyl-1-thio-β-d-glucosaminide is hydrolyzed by 
NAG and releases 6-methyl-2-pyridinethiol (MPT). The 
rate of increase of absorbance of MPT is measured at a 
wavelength of 340 nm to determine NAG activity in the 
sample. This assay is calibrated using a specific calibra-
tor supplied by the reagent manufacturer with a lot-spe-
cific value of NAG activity. The urine albumin level was 
measured by an immunoturbidimetric method using an 
AU680 automated chemistry analyzer (Beckman Coulter, 
Inc., Brea, CA, USA). The urine creatinine level was also 
measured using the AU680 analyzer (Beckman Coulter, 
Inc.) by the kinetic Jaffe method.
Measurements of carotid IMT
Protocols for measurements of IMT in both carotid 
arteries were described in detail previously [16]. Two 
specialized technicians conducted common carotid arte-
rial ultrasound examinations using an Aloka ProSound 
ALPHA 10 (HITACHI, Tokyo, Japan) with a 13 MHz lin-
ear probe. IMT was defined as the distance between the 
media-adventitia interface and the lumen-intima inter-
face. Mean IMT was defined as the average mean IMT 
of the right and left carotid arteries. Maximum IMT was 
the IMT value at the maximal point of the region, and 
the mean of maximum IMT was defined as the average 
of the maximum IMT values for both the right and left 
carotid arteries. Carotid plaques were defined accord-
ing to the Mannheim consensus [17], in which a plaque 
is diagnosed when the vessel wall thickness is >1.5  mm 
or when the vessel wall appears to be at least 0.5 mm, or 
50%, thicker than the surrounding wall. The presence of 
carotid plaques was positive when one or more carotid 
plaques existed.
Statistical analyses
All statistical analyses were performed using SPSS ver-
sion 20.0 for Windows (IBM Corp., Armonk, NY, USA). A 
normality test was performed for all continuous variables. 
The data are presented as mean ± standard deviation (SD) 
for normally distributed continuous variables and median 
(interquartile range) for non-normally distributed continu-
ous variables. Categorical data are expressed as numbers 
and percentages. Urinary NAG-to-creatinine ratio was 
categorized into two groups: at or below the median NAG 
ratio (≤7.21  U/g creatinine) and above the median NAG 
ratio (>7.21 U/g creatinine). Categories of albuminuria were 
defined as follows: normal to mildly increased albuminuria 
(ACR < 30 mg/g creatinine) and moderate to severe albu-
minuria (ACR ≥ 30 mg/g creatinine). The characteristics of 
the study participants were analyzed depending on urinary 
NAG level or the presence of carotid plaques using Mann–
Whitney U or two-sample Student’s t tests for continuous 
variables and a Pearson χ2 tests for categorical variables. 
Correlations between urinary NAG, urinary ACR, IMT, 
and other parameters were analyzed with Spearman’s cor-
relation coefficients. Backward multiple linear regression 
analysis was performed on logarithm-transformed values 
of maximum or mean of maximum IMT in order to model 
the relationship between the IMT and demographic and 
laboratory parameters, including urinary NAG. Multiple 
logistic regression analyses were conducted to assess odds 
ratios (ORs) for predicting the presence of carotid plaques. 
In regression analyses, age was a binary variable defined 
as < or ≥40 years of age, which is when patients with T2D 
begin to be at high risk for CVD [18]. All P values <0.05 
were considered statistically significant.
Results
Characteristics of the study participants depending 
on urinary NAG level
A total of 343 participants (203 men and 140 women) 
were enrolled in this study. The mean age and median 
duration of diabetes were 59.9 and 9.25  years, respec-
tively. The median value of urinary NAG was 7.21  U/g 
creatinine. The participants were divided into two 
groups: at or below the median urinary NAG (Group I; 
urinary NAG, 4.89 (3.70–6.21) U/g creatinine) and above 
the median urinary NAG (Group II; urinary NAG, 11.4 
(8.72–16.7) U/g creatinine). The demographics and labo-
ratory characteristics of the participants are shown in 
Table  1. Age, duration of diabetes, and history of coro-
nary artery disease were significantly higher in Group II 
than in Group I. Gender distribution, current smoking 
status, and history of hypertension or ischemic stroke 
were similar between the two groups. There were no 
significant differences in the proportions of participants 
taking glucose-lowering drugs, lipid-lowering drugs, 
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angiotensin-converting-enzyme (ACE) inhibitors, angio-
tensin receptor blockers (ARBs), diuretics, calcium chan-
nel blockers, or beta blockers between the groups, but 
participants receiving antiplatelet or anticoagulant agents 
were more frequent in Group II than in Group I (Addi-
tional file 1: Table S1).
With respect to laboratory indices, the participants 
in Group II had significantly higher levels of blood glu-
cose [HbA1C, GA, and basal and stimulated (postpran-
dial) glucose] than those in Group I. Lipid profiles and 
serum creatinine did not significantly differ between 
the groups, but eGFR values calculated by the CKD-EPI 
equation were significantly lower in Group II than in 
Group I.
Regarding indices of diabetes complications, urinary 
ACR was significantly increased in Group II compared 
with Group I. Mean, maximum, and mean of maximum 
carotid IMT and the proportion of patients with carotid 
plaques were significantly higher in Group II than in 
Group I.
Table 1 Baseline demographics and laboratory characteristics of participants
Continuous variables are described as mean ± SD for parametric variables and median (interquartile range) for nonparametric variables
NAG N-acetyl-β-d-glucosaminidase, BMI body mass index, HDL high density lipoprotein, LDL low density lipoprotein, eGFR estimated glomerular filtration rate, CKD-EPI 
chronic kidney disease epidemiology collaboration, ACR albumin-to-creatinine ratio, IMT intima-media thickness, SD standard deviation
Bolditalics denotes statistical significance at p < 0.05
a Median of NAG = 7.21 U/g creatinine
Baseline characteristics Total (N = 343) Group I
At or below mediana
NAG (N = 172)
Group II
Above median
NAG (N = 171)
p values
Demographics
 Age (years) 59.9 ± 11.7 57.2 ± 11.7 62.5 ± 11.0 <0.001
 Male sex [n (%)] 203 (59.2) 101 (58.7) 102 (59.6) 0.86
 BMI (kg/m2) 25.1 (23.1–27.2) 24.8 (23.1–27.1) 25.3 (23.0–27.3) 0.32
 Waist circumference (cm) 87.8 ± 8.95 86.9 ± 8.90 88.7 ± 8.98 0.07
 Currently smoking [n (%)] 53 (15.5) 30 (17.4) 23 (13.5) 0.31
 Hypertension [n (%)] 208 (60.6) 97 (56.4) 111 (64.9) 0.14
 Systolic blood pressure (mmHg) 125.0 (116.0–133.0) 125.0 (115.0–132.3) 124.0 (117.0–133.0) 0.54
 Diastolic blood pressure (mmHg) 74.4 ± 11.0 74.4 ± 11.2 74.6 ± 10.6 0.89
 Coronary artery disease [n (%)] 89 (25.9) 35 (20.3) 54 (31.6) 0.02
 Ischemic stroke [n (%)] 30 (8.75) 16 (9.30) 14 (8.19) 0.72
 Duration of diabetes (years) 9.25 (5.25–16.3) 7.25 (4.42–13.3) 11.3 (6.25–17.3) 0.001
Laboratory indices
 HbA1C (%) 6.80 (6.40–7.40) 6.70 (6.40–7.10) 7.00 (6.50–7.70) 0.001
 Glycated albumin (%) 17.1 (15.7–19.5) 16.6 (15.3–18.6) 18.1 (16.0–21.7) <0.001
 Basal glucose (mg/dl) 128.0 (111.0–146.0) 124.0 (110.0–140.0) 131.0 (114.0–156.3) 0.001
 Stimulated glucose (mg/dl) 191.5 (154.8–236.3) 176.5 (140.3–214.8) 208.5 (170.8–255.8) <0.001
 Total cholesterol (mg/dl) 156.0 (131.0–184.0) 155.0 (130.0–185.0) 157.5 (136.3–183.0) 0.48
 Triglyceride (mg/dl) 116.0 (80.0–161.0) 115.0 (78.0–157.0) 118.5 (85.8–175.0) 0.28
 HDL cholesterol (mg/dl) 44.0 (39.0–53.0) 44.0 (40.0–52.0) 42.0 (38.0–53.0) 0.17
 LDL cholesterol (mg/dl) 83.6 (61.3–106.7) 81.6 (59.8–107.0) 84.6 (63.7–102.3) 0.90
 White blood cell count (103/µl) 6.46 (5.38–8.03) 6.41 (5.47–7.63) 6.55 (5.36–8.43) 0.50
 Uric acid (mg/dl) 5.00 (4.20–5.90) 5.30 (4.30–5.90) 4.90 (4.00–5.93) 0.16
 Creatinine (mg/dl) 0.79 (0.66–0.93) 0.77 (0.66–0.89) 0.82 (0.66–0.97) 0.12
 eGFR CKD‑EPI (ml/min/1.73 m2) 94.0 (82.0–101.0) 96.0 (88.0–104.0) 91.0 (78.0–99.0) <0.001
Indices of diabetes complications
 Urinary NAG (U/g creatinine) 7.21 (4.89–11.4) 4.89 (3.70–6.21) 11.4 (8.72–16.7) <0.001
 Urinary ACR (mg/g creatinine) 10.0 (5.58–22.6) 8.43 (4.90–17.8) 12.8 (6.54–34.6) <0.001
 Mean carotid IMT (mm) 0.69 (0.60–0.80) 0.67 (0.58–0.77) 0.72 (0.60–0.84) 0.02
 Maximum carotid IMT (mm) 0.85 (0.73–1.01) 0.82 (0.70–0.97) 0.90 (0.74–1.06) 0.01
 Mean of maximum carotid IMT (mm) 0.81 (0.69–0.94) 0.78 (0.66–0.91) 0.83 (0.71–0.98) 0.01
 Presence of carotid plaques [n (%)] 248 (72.3) 114 (66.3) 136 (79.5) 0.01
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Characteristics of the study participants depending on the 
presence of carotid plaques
The characteristics of the study participants depend-
ing on the presence of carotid plaques are shown in 
Additional file  2: Table S2. Compared with participants 
without carotid plaques, those with carotid plaques had 
higher age, longer duration of diabetes, and higher inci-
dences of hypertension, coronary artery disease, and 
ischemic stroke. Regarding laboratory indices, the levels 
of total cholesterol and low density lipoprotein (LDL) 
cholesterol were significantly lower in participants with 
carotid plaques, which was consistent with their greater 
likelihood of taking lipid-lowering agents. Also, eGFR 
CKD-EPI was significantly lower in participants with 
carotid plaques compared with those without carotid 
plaques. Both urinary NAG and ACR were significantly 
higher in participants with carotid plaques than in those 
without carotid plaques. Antiplatelet or anticoagulant 
agents, lipid-lowering agents, ACE inhibitors or ARBs, 
calcium channel blockers, and beta blockers were more 
frequently used in participants with carotid plaques com-
pared with those without carotid plaques.
Correlations between urinary NAG and carotid IMT 
and other parameters
Mean, maximum, and mean of maximum carotid IMT 
were positively correlated with age and waist circumfer-
ence and negatively correlated with diastolic blood pres-
sure, high density lipoprotein (HDL) cholesterol, and 
eGFR CKD-EPI (Table 2). However, measures of carotid 
IMT were not significantly correlated with duration of 
diabetes or blood glycemic parameters. Urinary NAG, 
measured as a continuous variable, was positively cor-
related with maximum carotid IMT and mean of maxi-
mum carotid IMT. When categorized into quartiles, 
urinary NAG was positively correlated with all measures 
of carotid IMT. However, urinary ACR was not signifi-
cantly correlated with measures of carotid IMT, either 
as a continuous variable or by quartile. The mean, maxi-
mum, and mean of maximum carotid IMT were higher 
in the high urinary NAG group compared with the low 
urinary NAG group, whereas these differences were not 
found for urinary ACR (Fig. 1). When increased carotid 
IMT was defined as an IMT of >1 mm [19], the sensitiv-
ity of urinary NAG (>7.21 U/g creatinine; median value) 
and urinary ACR (≥30  mg/g creatinine) to identify an 
increased mean of maximum carotid IMT was 64.9 and 
31.6%, respectively.
Multiple linear regression analysis of factors affecting 
carotid IMT
To determine which factors predict carotid IMT, we 
performed multiple linear regression analyses (Table  3). 
Independent factors included in the model were age, 
eGFR CKD-EPI, urinary NAG, and urinary ACR, which 
were binary variables defined as <40 or ≥40 years, <60 or 
≥60 ml/min/1.73 m2, ≤7.21 or >7.21 U/g creatinine, and 
<30 or ≥30 mg/g creatinine, respectively. We tested three 
models separately. In Model 1, we entered demographic 
parameters including age, sex, waist circumference, cur-
rent smoking status, history of hypertension, and urinary 
NAG as independent factors and log transformed maxi-
mum or mean of maximum IMT as a dependent factor. 
Age, male gender, history of hypertension, and urinary 
NAG were significantly associated with both maximum 
and mean of maximum IMT. In Model 2, we addition-
ally adjusted for HDL cholesterol and urinary ACR. Age, 
history of hypertension, and urinary NAG were signifi-
cantly associated with maximum IMT, and age, history 
of hypertension, HDL cholesterol, and urinary NAG were 
significantly associated with mean of maximum IMT. 
Finally, further adjustment for eGFR CKD-EPI did not 
change the trends (Model 3).
Odds ratios for the presence of carotid plaques depending 
on urinary NAG and other risk variables
We performed multiple logistic regression analyses to 
investigate the association between carotid plaques 
and related risk factors, including urinary NAG, in par-
ticipants without history of coronary artery disease 
or ischemic stroke (Table  4). In our unadjusted model 
(Model 1), an above- median level of urinary NAG (OR 
1.96, 95% confidence interval (CI) 1.12–3.41, p  =  0.02) 
was significantly associated with the presence of carotid 
plaques. However, urinary ACR level (OR 2.33, 95% CI 
0.97–5.63, p =  0.06) was not significantly related to the 
presence of carotid plaques. After adjustment for age, 
sex, and history of hypertension, both urinary NAG and 
urinary ACR were significantly associated with the pres-
ence of carotid plaques (Model 2). After further adjust-
ment for use of lipid-lowering drugs and eGFR CKD-EPI, 
the associations between urinary NAG or urinary ACR 
and carotid plaques remained significant (Model 3).
Discussion
Renal tubular damage markers, including urinary NAG, 
have gained considerable attention because of their clini-
cal relevance as sensitive and specific biomarkers for 
predicting the development and progression of early-
stage DKD [11, 12]. Furthermore, there is accumulating 
evidence that urinary NAG is correlated or associated 
with vascular complications of T2D, including not only 
nephropathy but also retinopathy [13], neuropathy [14], 
and macrovascular disease [15]. However, there is no 
information on the relationship between urinary NAG 
excretion and carotid atherosclerosis in patients with 
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T2D. To our knowledge, only one study in patients with 
untreated hypertension has shown that urinary NAG 
excretion is positively associated with carotid IMT [20]. 
The aim of our study was to examine whether urinary 
NAG, a marker for renal tubulopathy, is more closely 
associated with carotid IMT and plaques in patients with 
T2D than albuminuria, a marker for renal glomerulopa-
thy. In this study, we demonstrated several important 
findings. First, regarding carotid IMT, mean, maximum, 
and mean of maximum carotid IMT were significantly 
higher in the high NAG group than the low NAG group. 
In correlation analyses, urinary NAG showed a signifi-
cant positive correlation with carotid IMT, whereas uri-
nary ACR did not correlate significantly with carotid 
IMT. After adjustment for clinical and laboratory risk 
variables, including age, sex, waist circumference, 
current smoking status, hypertension, HDL cholesterol, 
eGFR, and urinary ACR, urinary NAG independently 
predicted measures of carotid IMT. Second, in terms of 
carotid plaques, both urinary NAG and ACR were sig-
nificantly higher in participants with carotid plaques than 
in those without carotid plaques. In addition, having an 
above-median level of urinary NAG was associated with 
approximately twice the risk for the presence of carotid 
plaques compared with urinary NAG levels at or below 
the median. After adjustment for confounding variables, 
both urinary NAG and urinary ACR were significantly 
associated with the presence of carotid plaques.
Recently, attention to renal tubular damage markers as 
potential risk factor indicators for CVD is growing. There 
is accumulating evidence that urinary NAG is associated 
with various vascular diseases in different populations. 
Table 2 Correlations between urinary NAG and carotid IMT and other parameters in T2D (N = 343)
NAG N-acetyl-β-d-glucosaminidase, IMT intima-media thickness, T2D type 2 diabetes mellitus, BMI body mass index, HDL high density lipoprotein, LDL low density 
lipoprotein, eGFR estimated glomerular filtration rate, CKD-EPI chronic kidney disease epidemiology collaboration, ACR albumin-to-creatinine ratio
Bolditalics denotes statistical significance at p < 0.05
Baseline characteristics Urinary NAG Mean
IMT
Maximum IMT Mean of maximum 
IMT
r p r p r p r p
Demographics
 Age (years) 0.27 <0.001 0.47 <0.001 0.44 <0.001 0.45 <0.001
 BMI (kg/m2) 0.03 0.54 0.08 0.16 0.10 0.06 0.10 0.07
 Waist circumference (cm) 0.09 0.11 0.13 0.01 0.17 0.001 0.17 0.002
 Systolic blood pressure (mmHg) 0.03 0.59 0.09 0.10 0.10 0.06 0.11 0.04
 Diastolic blood pressure (mmHg) 0.002 0.97 −0.24 <0.001 −0.23 <0.001 −0.22 <0.001
 Duration of diabetes (years) 0.20 <0.001 0.11 0.05 0.10 0.06 0.10 0.06
Laboratory indices
 HbA1C (%) 0.21 <0.001 −0.07 0.19 −0.04 0.48 −0.05 0.36
 Glycated albumin (%) 0.27 <0.001 0.03 0.61 0.04 0.50 0.04 0.52
 Basal glucose (mg/dl) 0.20 <0.001 −0.10 0.06 −0.06 0.29 −0.07 0.22
 Stimulated glucose (mg/dl) 0.32 <0.001 0.02 0.70 0.07 0.19 0.06 0.30
 Total cholesterol (mg/dl) 0.03 0.56 −0.04 0.43 −0.02 0.71 −0.03 0.58
 Triglyceride (mg/dl) 0.04 0.50 −0.04 0.42 −0.02 0.77 −0.03 0.54
 HDL cholesterol (mg/dl) −0.14 0.01 −0.16 0.002 −0.15 0.01 −0.16 0.002
 LDL cholesterol (mg/dl) 0.02 0.74 0.04 0.48 0.04 0.51 0.04 0.50
 White blood cell count (103/µl) 0.03 0.70 0.04 0.64 0.12 0.16 0.07 0.44
 Uric acid (mg/dl) −0.12 0.03 0.08 0.14 0.10 0.07 0.09 0.08
 eGFR CKD‑EPI (ml/min/1.73 m2) −0.22 <0.001 −0.31 <0.001 −0.31 <0.001 −0.30 <0.001
Indices of diabetes complications
 Urinary NAG (U/g creatinine) 1 – 0.10 0.07 0.11 0.04 0.11 0.05
 Urinary NAG, quartile – – 0.12 0.03 0.13 0.01 0.13 0.02
 Urinary ACR (mg/g creatinine) 0.24 <0.001 0.07 0.19 0.07 0.22 0.08 0.16
 Urinary ACR, quartile 0.23 <0.001 0.05 0.36 0.04 0.48 0.05 0.33
 Mean carotid IMT (mm) 0.10 0.07 1 – 0.93 <0.001 0.97 <0.001
 Maximum carotid IMT (mm) 0.11 0.04 0.93 <0.001 1 – 0.97 <0.001
 Mean of maximum carotid IMT (mm) 0.11 0.05 0.97 <0.001 0.97 <0.001 1 –
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In the GISSI-Prevenzione trial targeting subjects with 
chronic heart failure [21], urinary NAG level was consist-
ently and strongly related to poor outcomes. In studies 
of type 1 or type 2 diabetes, retinopathy and peripheral 
neuropathy correlated with urinary NAG [13, 14, 22]. 
Weitgasser et  al. [15] showed the association of urinary 
NAG with macrovascular disease in elderly T2D patients. 
That study investigated patients with T2D during a 
median follow-up of 7  years and showed that urinary 
NAG is comparable to albuminuria as an indicator of the 
preexistence and development of severe macrovascular 
disease, including myocardial infarction and peripheral 
vascular disease. Regarding subjects without diabetes, 
Ouchi et  al. [23] reported that elevated urinary NAG 
is related to elevated arterial stiffness assessed by bra-
chial-ankle PWV. In a study including a low-risk general 
population, urinary NAG and ACR were independently 
associated with first-ever myocardial infarction, first-ever 
ischemic stroke, and all-cause mortality. However, NAG 
did not add to the risk predicted by traditional cardiovas-
cular risk factors, such as eGFR and ACR [24].
With respect to the relationship between albuminu-
ria as a glomerular damage marker and subclinical ath-
erosclerosis as assessed by IMT, although the association 
of albuminuria with CVD has been well-established in 
a number of populations, including diabetics, hyper-
tensive patients, and general subjects [25, 26], the rela-
tionship between carotid IMT and albuminuria is still 
controversial, as some studies show conflicting results. 
Among studies of patients with T2D, Ishimura et al. [2] 
and Ito et  al. [27] reported that the significant associa-
tion between these two parameters was lost after adjust-
ment for traditional risk factors such as blood pressure 
and waist-hip ratio. There may be several explanations for 
this discrepancy. First, diabetes itself has such a power-
ful influence on carotid IMT that any effect of albuminu-
ria could be masked [9]. Second, the study populations 
differed in terms of age, duration of diabetes, eGFR, 
ethnicity, and the use of methods of measuring carotid 
atherosclerotic lesions [27].
Only a single study, to our knowledge, has investigated 
the association between subclinical atherosclerosis of 
IMT and urinary NAG [20]. It showed that urinary NAG 
and carotid IMT or PWV were positively correlated 
and that carotid IMT and PWV had significant positive 
effects on urinary NAG in regression analyses of patients 
with untreated hypertension. In the present study, we 
observed that measures of carotid IMT were signifi-
cantly associated with urinary NAG rather than with uri-
nary ACR in simple correlation and regression analyses. 
Fig. 1 a Mean carotid IMT difference between high and low levels of urinary NAG or urinary ACR. b Maximum carotid IMT difference between high 
and low levels of urinary NAG or urinary ACR. c Mean of maximum carotid IMT difference between high and low levels of urinary NAG or urinary 
ACR (N = 343). IMT intima‑media thickness, NAG N‑acetyl‑β‑d‑glucosaminidase, ACR albumin‑to‑creatinine ratio. Each bar represents the median. 
Significance was tested using Mann‑Whitney U tests. Urinary NAG: low group, ≤7.21 U/g creatininea; high group, >7.21 U/g creatinine. Urinary ACR: 
low group, <30 mg/g creatinine; high group, ≥30 mg/g creatinine. aMedian value of urinary NAG
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Because of the cross-sectional design of our study, pos-
sible mechanisms for the relationship between urinary 
NAG and carotid IMT remain unclear. There is evidence 
that chronic tubulointerstitial hypoxia and increased oxi-
dative stress may play a pathogenic role in early stages of 
DKD [28], which in turn is related to the development 
of CVD. Furthermore, increased urinary NAG is a sen-
sitive marker of tubular injury related to inflammation 
and oxidative stress [24]. Therefore, the elevation of uri-
nary NAG, a renal interstitial marker, might reflect the 
severity of interstitial changes that result from athero-
sclerosis and subsequent ischemic injury [23]. In addi-
tion, the association between urinary NAG and carotid 
IMT might be mediated by several common risk factors. 
Consistent with previous reports [29], we observed that 
both urinary NAG and measures of carotid IMT were 
positively correlated with age and negatively correlated 
with eGFR, which are well-known risk factors for both 
DKD and systemic atherosclerosis. Nevertheless, we 
found several differences in the correlations of urinary 
NAG versus measures of carotid IMT with metabolic 
variables, including glucose-homeostasis and blood pres-
sure. We previously suggested that increased urinary 
NAG is related to glycemic parameters reflecting glu-
cose fluctuation (e.g., postprandial glucose rather than 
fasting glucose, GA rather than HbA1C) and decreased 
insulin secretory capacity as assessed by HOMA-β or 
postprandial C-peptide-to-glucose ratio (PCGR) in 
patients with T2D [12]. Regarding plausible explana-
tions for associations between glucose fluctuation and 
increases in urinary NAG excretion, we suggested the 
possibility of a physiologic increase in urinary NAG for 
metabolizing urinary glucose and a nephrotoxic effect of 
glycated end products on renal proximal tubules. NAG 
is an enzyme involved in carbohydrate metabolism; 
thus, when the proximal tubules are exposed to high 
urinary glucose, NAG might be more highly secreted in 
the urine, depending on urinary glucose concentrations 
Table 3 Multiple linear regression models for carotid IMT in T2D (N = 343)
Logarithm-transformed values of maximum and mean of maximum carotid IMT were used for analysis
Model 1: adjusted for age, sex, waist circumference, current smoking status, history of hypertension, and urinary NAG
Model 2: adjusted for Model 1 + HDL cholesterol and urinary ACR
Model 3: adjusted for Model 2 + eGFR CKD-EPI
IMT intima-media thickness, T2D type 2 diabetes mellitus, STD standardized; HDL: high density lipoprotein, eGFR: estimated glomerular filtration rate, CKD-EPI chronic 
kidney disease epidemiology collaboration, NAG N-acetyl-β-d-glucosaminidase; ACR albumin-to-creatinine ratio
Bolditalics denotes statistical significance at p < 0.05
a Age, b eGFR CKD-EPI, c urinary NAG, and d urinary ACR were analyzed as binary variables defined as < or ≥40 years, < or ≥60 ml/min/1.73 m2, ≤ or >7.21 U/g 
creatinine (median of NAG = 7.21 U/g creatinine), and < or ≥30 mg/g creatinine, respectively
Variables Model 1 Model 2 Model 3
STD β p STD β p STD β p
Log maximum IMT
 Agea 0.19 0.003 0.19 0.003 0.19 0.003
 Male gender 0.12 0.045
 Waist circumference (cm)
 Currently smoking
  History of hypertension 0.15 0.02 0.14 0.03 0.14 0.03
  HDL cholesterol (mg/dl) – –
  eGFR CKD‑EPIb – – – –
  Urinary NAGc 0.14 0.03 0.14 0.02 0.14 0.02
  Urinary ACRd – –
Log mean of maximum IMT
 Agea 0.19 0.003 0.18 0.004 0.18 0.004
 Male gender 0.12 0.04
 Waist circumference (cm)
 Currently smoking
  History of hypertension 0.13 0.04 0.13 0.04 0.13 0.04
  HDL cholesterol (mg/dl) – – −0.13 0.03 −0.13 0.03
  eGFR CKD‑EPIb – – – –
  Urinary NAGc 0.13 0.03 0.13 0.03 0.13 0.03
  Urinary ACRd – –
Page 9 of 11Kim et al. Cardiovasc Diabetol  (2017) 16:16 
[30]. In addition, the peptides derived from advanced 
glycation end products could have a nephrotoxic effect 
on the proximal tubule, thus contributing to the occur-
rence of proximal tubule injury [31]. We previously sug-
gested [32] that serum GA is more closely associated 
with postprandial glucose than fasting glucose and might 
be a useful index for monitoring fluctuating and poorly 
controlled glycemic excursions. The clinical relevance of 
GA could be attributed to observations that increased 
GA rather than HbA1C is significantly correlated with 
insulin secretory beta-cell function as assessed by PCGR 
and HOMA-β and that GA increases as the duration 
of diabetes lengthens [33]. Despite the lack of associa-
tion between HbA1C and IMT, consistent with previous 
studies [34], increasing waist circumference was associ-
ated only with measures of carotid IMT, which could be 
explained by the association of insulin resistance with 
increased IMT [35, 36]. However, neither urinary NAG 
nor measures of carotid IMT were significantly associ-
ated with BMI [37]. Urinary NAG was not related to high 
blood pressure, as was noted in a previous study [15], 
whereas measures of carotid IMT were negatively corre-
lated with diastolic blood pressure.
There is a well-established association between urinary 
ACR and carotid plaques in patients with T2D [10, 38]. In 
this study, we found that the presence of carotid plaques 
was associated with age, long duration of diabetes, his-
tory of hypertension, coronary artery disease, or ischemic 
stroke, reduction in eGFR, and increases in both urinary 
ACR and urinary NAG. An above-median level of uri-
nary NAG (OR 1.96, 95% CI 1.12–3.41, p = 0.02) was sig-
nificantly associated with the presence of carotid plaques. 
However, urinary ACR levels (OR 2.33, 95% CI 0.97–5.63, 
p =  0.06) were not significantly related to the presence 
of carotid plaques in an unadjusted model. After adjust-
ment for age, sex, and history of hypertension, both uri-
nary NAG and urinary ACR were significantly associated 
with the presence of carotid plaques. After further adjust-
ment to use lipid-lowering drugs and eGFR CKD-EPI, 
the associations between urinary NAG or urinary ACR 
and carotid plaques remained significant. These results 
show that urinary NAG is comparable to urinary ACR in 
predicting the presence of carotid plaques. To our knowl-
edge, this is the first time the relationship between uri-
nary NAG and carotid plaques has been investigated.
The current study has several strengths. First, our 
study provides clinical evidence supporting associations 
between urinary NAG and various vascular complica-
tions of diabetes. Second, we investigated whether uri-
nary NAG, a renal tubulopathic marker, is more closely 
associated with carotid atherosclerosis than the glo-
merulopathic marker albuminuria, which might rein-
force the comparability between markers. Additionally, 
we conducted the study with a relatively large number 
of subjects in a single center trial, which strengthens the 
statistical reliability of the results. However, the current 
study also has some limitations. First, because of the 
inherent drawbacks of cross-sectional studies, we cannot 
infer any causal or temporal relationships between uri-
nary NAG and carotid atherosclerosis. Second, the values 
of Spearman’s correlation coefficients between urinary 
NAG and measures of carotid IMT were statistically sig-
nificant but of only slight to fair magnitude. The process 
of increasing IMT is a complex phenomenon that is not 
only determined by pure atherosclerotic risk factors [39]. 
Thus, multifactorial determinants of IMT may reduce the 
statistical significance of urinary NAG. Finally, we did not 
compare the sensitivity of detecting carotid atheroscle-
rosis of urinary NAG using other renal tubular damage 
markers. For example, urinary liver-type fatty acid bind-
ing protein is also a sensitive marker of renal injury [40].
Conclusions
We evaluated the association of urinary NAG with sub-
clinical atherosclerosis as assessed by carotid IMT and 
revealed a novel finding that increased carotid IMT and 
the presence of carotid plaques are related to elevated 
urinary NAG, a marker of renal tubular damage, in 
patients with T2D. Furthermore, we found that urinary 
NAG might be a more sensitive urinary biomarker than 
urinary albumin for early detection of atherosclerosis. 
Further longitudinal prospective studies are needed to 
Table 4 Odds ratios for  the presence of  carotid plaques 
by  urinary NAG and  urinary ACR in  participants with-
out  history of  coronary artery disease or ischemic stroke 
(N = 232)
Presence of carotid plaques was defined as the existence of one or more carotid 
plaques
Model 1: unadjusted
Model 2: adjusted for age (< or ≥40 years), sex, and history of hypertension
Model 3: adjusted for age (< or ≥40 years), sex, history of hypertension, use of 
lipid-lowering drugs, and eGFR CKD-EPI (< or ≥60 ml/min/1.73 m2)
NAG N-acetyl-β-d-glucosaminidase, ACR albumin-to-creatinine ratio, ORs odds 
ratios, eGFR estimated glomerular filtration rate, CKD-EPI chronic kidney disease 
epidemiology collaboration
Bolditalics denotes statistical significance at p < 0.05
a Median of NAG = 7.21 U/g creatinine, b ACR < 30 mg/g creatinine, c 
ACR ≥ 30 mg/g creatinine
ORs (95% CI)
Urinary NAG (0 = at 
or below mediana, 
1 = above median)
Urinary ACR (0 = normoalbumi‑
nuriab, 1 = micro‑ or macroal‑
buminuriac)
Model 1 1.96 (1.12–3.41) 2.33 (0.97–5.63)
Model 2 1.88 (1.05–3.36) 3.42 (1.20–9.77)
Model 3 2.03 (1.12–3.68) 3.58 (1.25–10.3)
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investigate the causal relationship between renal tubular 
damage and systemic atherosclerosis and its mechanisms.
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